Director stock grant at Cytokinetics (CYTK) highlights equity retainer

Rhea-AI Filing Summary

WIERENGA WENDELL reported acquisition or exercise transactions in this Form 4 filing.

Cytokinetics Inc. director Wendell Wierenga received a grant of 75 shares of common stock on July 15, 2026, at $82.62 per share under the company’s Equity in lieu of Cash Retainer Program. The shares were fully vested at grant, bringing his direct holdings to 35,563 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider WIERENGA WENDELL

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	75	$82.62	$6K

Holdings After Transaction: Common Stock — 35,563 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Shares granted: 75 shares Grant price: $82.62 per share Shares owned after grant: 35,563 shares

3 metrics

Shares granted 75 shares Common stock grant to director Wendell Wierenga on July 15, 2026

Grant price $82.62 per share Transaction price for the 75-share common stock award

Shares owned after grant 35,563 shares Director Wendell Wierenga’s direct holdings following the reported transaction

Key Terms

Equity in lieu of Cash Retainer Program, fully vested

2 terms

Equity in lieu of Cash Retainer Program financial

"granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program"

fully vested financial

"Shares are fully vested at the time of grant"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/16/2026 - 04:34 PM Accepted by SEC EDGAR 07/16/2026 - 04:34 PM Learn about SEC filing dates

FAQ

What insider stock grant did CYTK report for Wendell Wierenga?

Cytokinetics reported that director Wendell Wierenga received a grant of 75 shares of common stock at $82.62 per share on July 15, 2026. The award came through the Equity in lieu of Cash Retainer Program and was fully vested immediately.

How many CYTK shares does Wendell Wierenga hold after this Form 4 transaction?

Following the grant, Wendell Wierenga directly holds 35,563 shares of Cytokinetics common stock. This total includes the newly awarded 75 shares reported in the Form 4 and reflects his updated direct ownership position as of July 15, 2026.

What was the price used for the CYTK stock grant to Wendell Wierenga?

The grant to Wendell Wierenga was valued at $82.62 per share for 75 shares of Cytokinetics common stock. This price is the transaction price disclosed for the fully vested award under the company’s Equity in lieu of Cash Retainer Program.

What is Cytokinetics' Equity in lieu of Cash Retainer Program mentioned for CYTK?

The Equity in lieu of Cash Retainer Program provides shares of common stock instead of a cash retainer to eligible participants. In this case, Wendell Wierenga received 75 fully vested shares of Cytokinetics common stock under the program as compensation for his board service.

Was the CYTK stock award to Wendell Wierenga subject to vesting conditions?

The award was fully vested at the time of grant, with no additional vesting schedule. Cytokinetics disclosed that the 75 shares of common stock issued to Wendell Wierenga under the Equity in lieu of Cash Retainer Program were immediately and entirely vested.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WIERENGA WENDELL

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/15/2026		A(1)		75	A	$82.62	35,563	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.

	/s/ John O. Faurescu, attorney-in-fact for Dr. Wierenga	07/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)